Kovack Advisors Inc. Buys 175 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Kovack Advisors Inc. increased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,402 shares of the company’s stock after purchasing an additional 175 shares during the quarter. Kovack Advisors Inc.’s holdings in GE HealthCare Technologies were worth $266,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in GEHC. LGT Financial Advisors LLC grew its position in shares of GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of GE HealthCare Technologies during the third quarter worth about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of GE HealthCare Technologies during the third quarter worth about $26,000. Darwin Wealth Management LLC purchased a new stake in shares of GE HealthCare Technologies during the third quarter worth about $31,000. Finally, Continuum Advisory LLC grew its position in shares of GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

Shares of GE HealthCare Technologies stock opened at $87.35 on Friday. The stock has a market cap of $39.94 billion, a price-to-earnings ratio of 20.17, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The stock has a 50 day moving average price of $86.17 and a 200-day moving average price of $86.12. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The firm had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. Equities analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wells Fargo & Company increased their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Citigroup raised their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price target for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.67.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.